Key Highlights
- Halda Therapeutics names Christian Schade as President and CEO.
- Schade brings over 20 years of biotech leadership experience.
- RIPTAC™ cancer therapies on track for clinical trials in 2025.
- Focus on prostate and breast cancer treatments with unmet needs.
Source: Business Wire
Notable Quotes
- “With Chris’ outstanding leadership, Halda is well positioned to realize the full potential of the RIPTAC modality.” — Tim Shannon, Chair of Halda’s Board of Directors at Canaan Partners
- “I am delighted to join the talented team at Halda that has made impressive progress advancing the RIPTAC platform.” — Christian Schade, President and CEO at Halda Therapeutics
SoHC's Take
Christian Schade’s appointment as President and CEO of Halda Therapeutics is a strategic move that aligns with the company’s goal of advancing its innovative RIPTAC™ platform into clinical development. His extensive experience in steering biotech companies through pivotal growth phases and his successful track record in leading IPOs and high-profile acquisitions position Halda for success as it targets prostate and breast cancer treatments—two areas with significant unmet patient needs. With RIPTAC’s unique “hold and kill” mechanism set to enter clinical trials in 2025, Halda is poised to make a meaningful impact in precision oncology.
